{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:04:17Z","timestamp":1793318657698,"version":"4.5.0"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2825,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1111\/j.1365-2133.2007.08357.x","type":"journal-article","created":{"date-parts":[[2008,2,11]],"date-time":"2008-02-11T04:04:21Z","timestamp":1202702661000},"page":"592-596","source":"Crossref","is-referenced-by-count":162,"title":["Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy"],"prefix":"10.1093","volume":"158","author":[{"given":"C-H.","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W-C.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C-K.","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y-C.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S-T.","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y-C.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T-T.","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J-J.","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.W.C.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2007,12,7]]},"reference":[{"key":"10.1111\/j.1365-2133.2007.08357.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/j.1365-2133.2006.07452.x","article-title":"The PRIDE (Papulopustules and\/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) syndrome","volume":"155","author":"Lacouture","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2007.08357.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2133.2007.08357.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1200\/JCO.2005.03.6723","article-title":"Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma","volume":"24","author":"Ratain","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1365-2133.2007.08357.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1359-6349(06)70111-2","article-title":"A prospective study of the cutaneous side effects of sorafenib, a novel multi-kinase inhibitor","volume":"4","author":"Auiter","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1111\/j.1365-2133.2007.08357.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1200\/JCO.2006.08.9565","article-title":"Hand-foot and stump syndrome to sorafenib","volume":"25","author":"Lai","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1365-2133.2007.08357.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1200\/JCO.2005.06.124","article-title":"Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors","volume":"23","author":"Strumberg","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1365-2133.2007.08357.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"6771","DOI":"10.1200\/JCO.2005.08.036","article-title":"Raf: a strategic target for therapeutic development against cancer","volume":"23","author":"Beeram","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1365-2133.2007.08357.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.2005.02.2194","article-title":"Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer","volume":"24","author":"Faivre","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1365-2133.2007.08357.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/00128071-200001040-00004","article-title":"Antineoplastic therapy-induced palmar plantar erythrodysesthesia (\u2018hand-foot\u2019) syndrome. Incidence, recognition and management","volume":"1","author":"Nagore","year":"2000","journal-title":"Am J Clin Dermatol"},{"key":"10.1111\/j.1365-2133.2007.08357.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1468-3083.1998.tb00752.x","article-title":"Cytarabine-induced acral erythema: a localized form of toxic epidermal necrolysis?","volume":"10","author":"Calista","year":"1998","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/j.1365-2133.2007.08357.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1001\/archderm.136.12.1475","article-title":"Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin","volume":"136","author":"Lotem","year":"2000","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2007.08357.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"5786","DOI":"10.1200\/JCO.2006.08.6868","article-title":"Hand-foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma","volume":"24","author":"Tsai","year":"2006","journal-title":"J Clin Oncol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2133.2007.08357.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2133.2007.08357.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T09:23:47Z","timestamp":1676366627000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/158\/3\/592\/6643787"}},"subtitle":["Hand-foot skin reaction in sorafenib-treated patients"],"short-title":[],"issued":{"date-parts":[[2007,12,7]]},"references-count":12,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2133.2007.08357.x","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,12,7]]}}}